| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ito Y | [Progress of molecularly targeted therapy for breast cancer]. | 2012 | Rinsho Ketsueki | pmid:22687976 |
| Dixon JM et al. | HER2 testing in patients with breast cancer. | 2012 | BMJ | pmid:22689887 |
| Davis JA et al. | In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates. | 2012 | Drug Metab. Dispos. | pmid:22752008 |
| Younes A et al. | Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. | 2012 | J. Clin. Oncol. | pmid:22753910 |
| Wings S et al. | A study of the bacterial community in the root system of the maytansine containing plant Putterlickia verrucosa. | 2013 | Phytochemistry | pmid:22795602 |
| Erickson HK and Lambert JM | ADME of antibody-maytansinoid conjugates. | 2012 | AAPS J | pmid:22875610 |
| Bender BC et al. | A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. | 2012 | Cancer Chemother. Pharmacol. | pmid:22886072 |
| Beck A et al. | Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. | 2012 Nov-Dec | MAbs | pmid:22909934 |
| Matsubara Y | A Meg by any other name. | 2012 | Blood | pmid:22956528 |
| Chudasama VL et al. | Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. | 2012 | Clin. Pharmacol. Ther. | pmid:22968044 |
| Suwanborirux K et al. | Ansamitocin P-3, a maytansinoid, from Claopodium crispifolium and Anomodon attenuatus or associated actinomycetes. | 1990 | Experientia | pmid:2298279 |
| Garzone PD and Atkinson AJ | In search of physiologically based distribution volume estimates for macromolecules. | 2012 | Clin. Pharmacol. Ther. | pmid:22992670 |
| Verma S et al. | Trastuzumab emtansine for HER2-positive advanced breast cancer. | 2012 | N. Engl. J. Med. | pmid:23020162 |
| Siyu-Mao et al. | Two novel ansamitocin analogs from Actinosynnema pretiosum. | 2013 | Nat. Prod. Res. | pmid:23061718 |
| Interest in "smart bombs" explodes. | 2012 | Cancer Discov | pmid:23071018 | |
| Bander NH et al. | Antibody-drug conjugate technology development for hematologic disorders. | 2012 | Clin Adv Hematol Oncol | pmid:23072775 |
| Teicher BA and Doroshow JH | The promise of antibody-drug conjugates. | 2012 | N. Engl. J. Med. | pmid:23134386 |
| Barginear MF et al. | Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. | 2012 | Mol. Med. | pmid:23196784 |
| Pode-Shakked N et al. | The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets. | 2013 | EMBO Mol Med | pmid:23239665 |
| Konecny GE | Emerging strategies for the dual inhibition of HER2-positive breast cancer. | 2013 | Curr. Opin. Obstet. Gynecol. | pmid:23241641 |